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 Abstract: 
Aim: To provide knowledge that topical steroids and topical non-steroidal antiinflammatory drugs "NSAIDs"; 
can cure cystoid macular edema "CME"; which is 
currently mostly treated by invasive procedures "i.e. intravitreal steroids and anti 
VEGF, laser and vitrectomy". 
Introduction: Through many years ever since the CME has been discovered by Irvin, 
invasive interventions were regarded as the most effective curative modalities of 
treatment. Recently it was proved that there is an inflammatory reaction in the process 
of CME formation, based on that evidence many studies started aiming at evaluating the 
role of anti-inflammatory agents in the treatment of CME. 
Case presentation: A 60 years old gentleman presented with deterioration of vision in 
his right eye over 45 days, he is on antiglaucoma medications and has undergone a 
glaucoma surgery two years back, there were no any associated systemic symptoms or 
diseases. On examination: the left eye was diagnosed as end stage glaucoma and so it 
was excluded from the examination; on examination of the right eye: best corrected 
visual acuity was 6/36; intra ocular pressure "IOP" 10 mmHg, dilated fundus 
examination: Optic disc: glaucomatous atrophy, Vessels: attenuated arterial system and 
congested venous system, Macula: dull with irregular slit lamp light appearance 
indicating microcysts formation; and Periphery: was non informative, Ocular Coherent 
Tomography "OCT": showed marked increased thickness of the retinal layers with cysts 
formation at the macular area. Accordingly the patient was diagnosed as cystoid macular 
edema and hence the plan was to put him on topical steroids and topical NSAIDs eye 
drops qid, a regular follow up and measurement of IOP. 
Results: OCT repeated after a month and there were no obvious changes, four months 
later OCT showed a remarkable improvement; i.e. the thickness is much lesser, another 
OCT after a further month showed complete resolution of the edema, and best corrected 
visual acuity was 6/24. 
Discussion and Conclusion: CME is in part an inflammatory condition; so it could 
possibly be treated with anti-inflammatory agents, such as topical steroids and NSAIDs, 
as it is evident in this case CME can be totally cured without the need of invasive 
procedures. 
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Introduction:   
Cystoid macular edema arises due to the breakdown of the blood-retinal barrier causing accumulation of 
fluid within the retina, specifically between the inner nuclear and outer plexiform layers, resulting in a 
“flower petal” appearance 1.The exact etiology is unknown, most often it follows a previous ocular surgery 
"glaucoma surgery in our case"; other risk factors may include: retinal vascular disease, inflammation, drug-
induced etc. Pathogenesis of CME is still obscure, it is perhaps a multifactorial, but most of the investigators 
agree that the major etiological factor especially in post operative CME is inflammation including 
EDITORIAL  
Gezira Journal Of Health Sciences 2014 vol.10(2)  
 
Gezira Journal Of Health Sciences 2014 vol.10(2) 
endogenous prostaglandin and other medical mediators, other factors include vitreous traction, 
endophthalmitis, and vascular instability etc2. A patient with CME may be asymptomatic or may complain 
of decreased vision, a positive central scotoma or metamorphopsia, clinically it is best detected by binocular 
slit lamp examination with the Goldmann fundus contact lens or Hruby lens; a loss of foveal reflex and 
depression and appearance of yellowish spot, rossette pattern can also be noticed3, Amsler grid is also 
helpful; then a final diagnosis can be reached by requesting OCT and/or Fluorescine angiography. 
Regarding the treatment, there are many options; in this case report we are concentrating on the outcome 
of topical NSAIDs and steroids. Topical NSAIDs inhibit the enzyme cyclooxygenase, which is required 
for the production of the prostaglandins as a degradation product of arachidonic acid. There is evidence that 
some NSAIDs may also act on other mediators; it can also be used as a prophylactic modality. Topical 
Steroids also inhibit the production of prostaglandins, but at a higher level in the biochemical pathway, by 
inhibiting the enzyme phospholipase A2, which catalyses the conversion of membrane lipids to arachidonic 
acid. By this process, steroids inhibit the formation of both prostaglandins and leukotrienes, locally their 
vasoconstrictive properties decrease intracellular and extracellular edema, suppress macrophage activity, 
and decrease lymphokine production. Clinical experience has shown that pseudophakic CME usually 
responds well to local therapy of steroids and NSAIDs and/or in association with systemic acetazolamide4.  
Literature review  
 Numerous studies have reported NSAIDs’ efficacy in the prophylaxis of pseudophakic CME. A meta-
analysis by Luca Rosetti, MD, and colleagues in 1998 concluded topical NSAID administration was 
beneficial in lowering the incidence of angiographically and clinically diagnosed pseudophakic CME. A 
randomized, controlled trial examined topical indomethacin for pseudophakic CME prophylaxis and 
treatment. The study of 189 eyes reported a pseudophakic CME incidence of 0 percent for eyes receiving 
preoperative and postoperative indomethacin, 15 percent for eyes receiving postoperative indomethacin 
only, and 33 percent for controls. Another large multicenter RCT reported improvement in visual acuity in 
the treatment of chronic aphakic and pseudophakic CME using 0.5% ketorolac (Acular, Allergan).Limited 
data is known about the long-term effects (>one year) of NSAIDs on pseudophakic CME5. It does appear 
that combination therapy with topical NSAID and corticosteroid may be superior to either individual 
therapy. A small, randomized control trial in 2000 compared topical ketorolac to topical prednisolone to 
combination therapy for the treatment of pseudophakic CME. Average improvement in Snellen visual 
acuity over three months was 1.6 lines in the ketorolac group, 1.1 lines in the prednisolone group and 3.8 
lines in the combination group. Perhaps a synergistic effect is observed with combination therapy, although 
more studies are needed5.  
  
Discusssion:    
 No doubt that CME constitutes a great challenge, as many factors can lead to CME; treatment options vary. 
Therapeutic interventions are based on the proposed pathogenesis of edema, mainly inflammation and 
vitreous traction5. For most retina specialists, the current primary treatment modality for CME consists of 
both a corticosteroid and an NSAID, administered topically. Prior to the development of NSAIDs that have 
improved posterior segment penetration, many retina specialists did not use topical NSAIDs. Treatment 
strategies have changed with the evolution of the currently available NSAIDs that offer better penetration, 
are effective in treating CME and may have an important role in reducing the incidence of CME. (6)  
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Conclusion:  
CME is still an area of ongoing research and further exploration both in regard to it's pathogenesis and 
management. So far there is no standardized regimen in treating CME. The difficulty is because that most 
of the CME cases resolve spontaneously in addition to the fact that there are no experimental models. Most 
of the lab animals have no macula and those which do have, their macula are resistant to CME, but as it 
was clearly proved in this case and from the literature reviews, and relying on that there is an inflammatory 
factor in CME, there are promising results supporting that topical medications "Steroids & NSAIDs" can 
lead to satisfying outcomes i.e. complete resolution of the CME, and visual acuity improvement, and they 
may even have a prophylactic role as well.   
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Summary:  
We recommend that it is better to start treating CME patient by topical steroids and NSAIDs eye drop with 
regular follow up before commencing invasive interventions. Though most of the CME patients can benefit 
from this protocol, some do need other modalities. So every patient has to be thoroughly assessed, and then 
the choice of treatment has to be tailored accordingly. We encourage more researches to be done in this 
subject, and in finding measurements to prevent its occurrence.  
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